首页 | 本学科首页   官方微博 | 高级检索  
     


Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study
Affiliation:1. University Hospitals Leuven and KU Leuven, Leuven, Belgium;2. Szpitale Wojewodzkie w Gdyni/Gdansk Medical University, Gdynia, Poland;3. Christie Hospital NHS Foundation Trust, Manchester, UK;4. Odense University Hospital, Odense, Denmark;5. Vall d’Hebrón Institute of Oncology and Vall d’Hebrón University Hospital, Barcelona, Spain;6. University Hospital Besançon, Besançon, France;7. Mount Vernon Hospital, Northwood, UK;8. Amsterdam University Medical Centers, Amsterdam;9. VieCuri Medisch Centrum Noord-Limburg, Venlo, The Netherlands;10. NN Blokhin National Medical Research Center of Oncology, Moscow, Russia;11. Moscow City Oncology Hospital N62, Moscow, Russia;12. Schwerpunktpraxis für Haematologie und Onkologie Hasselbachplatz, Magdeburg, Germany;13. Hospital General Universitario Gregorio Marañón, Madrid, Spain;14. Hammersmith Hospital, Imperial College London, London, UK;15. University Hospital of Pisa, Department of Oncology, Pisa, Italy;16. Institut de Recherches Internationales Servier, Suresnes, France;17. Saint-Petersburg Scientific Practical Center for Specialized Medical Care, St Petersburg, Russia
Abstract:
Keywords:bevacizumab  capecitabine  intensive therapy  metastatic colorectal cancer  TASCO1 study  trifluridine/tipiracil
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号